Uveitis Treatment Market 2024 Share, Size, Growth, Trends And Forecast 2032


(MENAFN- IMARC Group) IMARC Group's report titled“ Uveitis Treatment Market Report by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis), Cause (Infectious, Non-infectious), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2024-2032 “. The global uveitis treatment market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/uveitis-treatment-market/requestsample

Factors Affecting the Growth of the Uveitis Treatment Industry:

Rising Number of Uveitis Cases:

The escalating demand for uveitis treatment on account of the increasing number of uveitis cases among the masses around the world is contributing to the growth of the market. In addition, uveitis is characterized by inflammation of the uvea, which is the middle layer of the eye. It can cause vision impairment or even blindness if left untreated. Furthermore, people are suffering from uveitis cases due to changing demographics and environmental factors. Additionally, environmental factors, such as exposure to toxins and pollutants, can increase the risk of uveitis. Furthermore, the growing awareness among individuals about eye health and the importance of early detection is positively influencing the market.

Advancements in Medical Technology:

Advancements in diagnostic tools and treatment modalities assist in enhancing the accuracy of uveitis diagnosis, which is propelling the growth of the market. Besides this, modern imaging techniques, such as optical coherence tomography (OCT) and fluorescein angiography, enable healthcare professionals to visualize and assess uveitis-related inflammation with improved precision. This early and accurate diagnosis allows for timely intervention, improving patient outcomes. Furthermore, the rising development of targeted therapies and biologics is supporting the market growth. These advanced pharmaceuticals are often utilized in conjunction with traditional treatments like corticosteroids to offer more effective and less invasive options.

Increasing Geriatric Population:

The growing demand for uveitis treatment among the geriatric population is offering a positive market outlook. In line with this, uveitis is often associated with age-related conditions like sarcoidosis or age-related macular degeneration. Moreover, the natural aging process can weaken the immune system and make elderly individuals more susceptible to inflammatory eye conditions like uveitis. Besides this, elderly individuals are increasingly seeking medical care and treatment for eye-related issues, which is bolstering the growth of the market. Furthermore, the rising awareness about the importance of developing effective and accessible treatment options to address the specific needs of an aging population is impelling the market growth.

Leading Companies Operating in the Global Uveitis Treatment Industry:

  • AbbVie Inc.
  • Alimera Sciences Inc.
  • Bausch & Lomb Incorporated (Bausch Health)
  • Enzo Biochem Inc.
  • Eyegate Pharmaceuticals Inc.
  • Eyepoint Pharmaceuticals Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd.

Uveitis Treatment Market Report Segmentation:

By Treatment Type:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Corticosteroids represent the largest segment as they work by reducing inflammation in the eye and alleviating pain.



By Disease Type:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Anterior uveitis accounted for the largest market share due to the rising focus on early diagnosis among individuals.

By Cause:

  • Infectious
  • Non-infectious

Non-infectious holds the biggest market share as it arises when the immune system mistakenly targets and inflames the tissues of the eyes.

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Retail pharmacies exhibit a clear dominance in the market due to the wide availability of over the counter (OTC) uveitis medications.

Regional Insights:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

North America enjoys the leading position in the uveitis treatment market on account of the highly developed healthcare infrastructure.

Global Uveitis Treatment Market Trends:

The rising development of biologics and targeted therapies specifically designed for uveitis is contributing to the growth of the market. In line with this, targeted therapies assist in offering enhanced outcomes and fewer side effects for patients, which is bolstering the market growth.

The increasing commercialization of clinical trials for uveitis treatments benefits in improving the research and development (R&D) process, which is supporting the market growth. Apart from this, faster approvals are providing innovative treatment solutions to individuals across the globe.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

MENAFN22022024004122016232ID1107884112


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.